FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090817648> ?p ?o ?g. }

• W2090817648 endingPage "2039" @default.
• W2090817648 startingPage "2030" @default.
• W2090817648 abstract "BACKGROUND Children with Philadelphia (Ph) chromosome positive (+) acute lymphoblastic leukemia (ALL) represent a subgroup at very high risk for treatment failure. In this report, the authors assessed the outcome of Ph+ ALL in a large cohort of children treated on contemporary intensive chemotherapy protocols of the Children's Cancer Group (CCG). METHODS This study included 1322 children enrolled between 1988-1995 on CCG risk-adjusted studies for ALL who had centrally reviewed cytogenetic data. Thirty patients had a t(9;22)(q34;q11) translocation and were referred to as Ph+; 1292 were Ph negative(-). Outcome analyses used standard life table methods. RESULTS Compared with Ph- ALL patients, Ph+ ALL patients were more likely to be black (P = 0.008), age >10 years (P = 0.02), and have a leukocyte count ≥50,000/L (P < 0.0001). Nearly all Ph+ (96.7%) and Ph- (98.3%) patients achieved remission after induction therapy, yet event free survival outcome was significantly worse for Ph+ patients compared with Ph- patients, with 4-year estimates of 20.1% (standard deviation [SD] = 9.1%) and 75.8% (SD = 1.2%), respectively (P < 0.0001). This difference was maintained among patients regardless of presenting leukocyte count, age, or early response to therapy. Ten Ph+ patients underwent bone marrow transplantation (BMT) at the time of first remission; six of these patients remained event free at the time of analysis, and represent the majority (six of eight) of patients surviving event free. CONCLUSIONS The findings of the current study confirm that Ph chromosome positivity represents a significant independent adverse risk factor for childhood ALL that has not been abrogated by current intensive chemotherapy programs. BMT at the time of first remission, as well as other alternative strategies employing biotherapeutic agents, should be considered in future front-line trials for pediatric patients with Ph+ ALL. Cancer 1998;83:2030-2039. © 1998 American Cancer Society." @default.
• W2090817648 created "2016-06-24" @default.
• W2090817648 creator A5008518579 @default.
• W2090817648 creator A5018786888 @default.
• W2090817648 creator A5019914745 @default.
• W2090817648 creator A5021059238 @default.
• W2090817648 creator A5033167405 @default.
• W2090817648 creator A5033608060 @default.
• W2090817648 creator A5034653175 @default.
• W2090817648 creator A5063521126 @default.
• W2090817648 creator A5070896103 @default.
• W2090817648 creator A5084143877 @default.
• W2090817648 creator A5091381226 @default.
• W2090817648 date "1998-11-01" @default.
• W2090817648 modified "2023-10-14" @default.
• W2090817648 title "Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies" @default.
• W2090817648 cites W119643787 @default.
• W2090817648 cites W1544856870 @default.
• W2090817648 cites W1573670911 @default.
• W2090817648 cites W1776902603 @default.
• W2090817648 cites W1822941578 @default.
• W2090817648 cites W1884891985 @default.
• W2090817648 cites W1907019127 @default.
• W2090817648 cites W1974635745 @default.
• W2090817648 cites W19872180 @default.
• W2090817648 cites W2002433192 @default.
• W2090817648 cites W2008197447 @default.
• W2090817648 cites W2008690643 @default.
• W2090817648 cites W2016086822 @default.
• W2090817648 cites W2020954035 @default.
• W2090817648 cites W2030651277 @default.
• W2090817648 cites W2031841591 @default.
• W2090817648 cites W2038252730 @default.
• W2090817648 cites W2040323778 @default.
• W2090817648 cites W2043830012 @default.
• W2090817648 cites W2112997504 @default.
• W2090817648 cites W2119685895 @default.
• W2090817648 cites W2130096974 @default.
• W2090817648 cites W2138205116 @default.
• W2090817648 cites W2271992267 @default.
• W2090817648 cites W2276344482 @default.
• W2090817648 cites W2316252570 @default.
• W2090817648 cites W2395199156 @default.
• W2090817648 cites W2415399318 @default.
• W2090817648 cites W2418118875 @default.
• W2090817648 cites W2440705721 @default.
• W2090817648 cites W287437100 @default.
• W2090817648 cites W4293241248 @default.
• W2090817648 doi "https://doi.org/10.1002/(sici)1097-0142(19981101)83:9<2030::aid-cncr21>3.0.co;2-q" @default.
• W2090817648 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9806664" @default.
• W2090817648 hasPublicationYear "1998" @default.
• W2090817648 type Work @default.
• W2090817648 sameAs 2090817648 @default.
• W2090817648 citedByCount "118" @default.
• W2090817648 countsByYear W20908176482012 @default.
• W2090817648 countsByYear W20908176482013 @default.
• W2090817648 countsByYear W20908176482015 @default.
• W2090817648 countsByYear W20908176482016 @default.
• W2090817648 countsByYear W20908176482017 @default.
• W2090817648 countsByYear W20908176482019 @default.
• W2090817648 countsByYear W20908176482022 @default.
• W2090817648 countsByYear W20908176482023 @default.
• W2090817648 crossrefType "journal-article" @default.
• W2090817648 hasAuthorship W2090817648A5008518579 @default.
• W2090817648 hasAuthorship W2090817648A5018786888 @default.
• W2090817648 hasAuthorship W2090817648A5019914745 @default.
• W2090817648 hasAuthorship W2090817648A5021059238 @default.
• W2090817648 hasAuthorship W2090817648A5033167405 @default.
• W2090817648 hasAuthorship W2090817648A5033608060 @default.
• W2090817648 hasAuthorship W2090817648A5034653175 @default.
• W2090817648 hasAuthorship W2090817648A5063521126 @default.
• W2090817648 hasAuthorship W2090817648A5070896103 @default.
• W2090817648 hasAuthorship W2090817648A5084143877 @default.
• W2090817648 hasAuthorship W2090817648A5091381226 @default.
• W2090817648 hasBestOaLocation W20908176481 @default.
• W2090817648 hasConcept C104317684 @default.
• W2090817648 hasConcept C121608353 @default.
• W2090817648 hasConcept C126322002 @default.
• W2090817648 hasConcept C138626823 @default.
• W2090817648 hasConcept C151730666 @default.
• W2090817648 hasConcept C185592680 @default.
• W2090817648 hasConcept C187212893 @default.
• W2090817648 hasConcept C2778461978 @default.
• W2090817648 hasConcept C2778904597 @default.
• W2090817648 hasConcept C2779343474 @default.
• W2090817648 hasConcept C2909962599 @default.
• W2090817648 hasConcept C55493867 @default.
• W2090817648 hasConcept C71924100 @default.
• W2090817648 hasConcept C72563966 @default.
• W2090817648 hasConcept C86803240 @default.
• W2090817648 hasConcept C90924648 @default.
• W2090817648 hasConceptScore W2090817648C104317684 @default.
• W2090817648 hasConceptScore W2090817648C121608353 @default.
• W2090817648 hasConceptScore W2090817648C126322002 @default.
• W2090817648 hasConceptScore W2090817648C138626823 @default.
• W2090817648 hasConceptScore W2090817648C151730666 @default.
• W2090817648 hasConceptScore W2090817648C185592680 @default.
• W2090817648 hasConceptScore W2090817648C187212893 @default.

• next